Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 15

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 15
---
 risks and uncertainties that we do not currently know about or that we currently believe are not material may also adversely affect our business. If any of the risks and uncertainties described in this prospectus supplement or the documents incorporated by reference herein or other unknown or currently immaterial risks or uncertainties actually occur, our business, financial condition, results of operations and prospects could be adversely affected in a material way. The occurrence of any of these risks may cause you to lose all or part of your investment in the notes.

This prospectus supplement also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by us described below and elsewhere in this prospectus supplement. See “Information Concerning Forward-Looking Statements” in this prospectus supplement.

#### Risks Relating to the Notes
AMS Europe is a finance subsidiary and will depend on Boston Scientific or Boston Scientific’s other subsidiaries for funds to meet its obligations under the notes.

AMS Europe is a finance subsidiary of Boston Scientific and Boston Scientific conducts a significant portion of its operations through its subsidiaries. AMS Europe’s principal source of funds is its financing activities with Boston Scientific and the payments to AMS Europe by other Boston Scientific subsidiaries, and a significant portion of Boston Scientific’s source of funds, including funds to make payments pursuant to the guarantees of the notes, is dividends, loans or other payments to Boston Scientific by its subsidiaries. In addition, there may be statutory and regulatory limitations on the payment of dividends from certain subsidiaries of Boston Scientific. If AMS Europe has insufficient funds from its financing activities and sufficient funds are not able to be transferred to Boston Scientific from its subsidiaries, or to AMS Europe from other Boston Scientific subsidiaries, or sufficient cash or liquidity is not otherwise available, AMS Europe and Boston Scientific may not be able to make principal, premium or interest payments on outstanding debt, including under the notes and the guarantees.

The notes will not be guaranteed by any of Boston Scientific’s other subsidiaries and will be structurally subordinated to the debt and other liabilities of our subsidiaries (other than AMS Europe).

The notes will be obligations of AMS Europe and will be guaranteed exclusively by Boston Scientific and not by any of Boston Scientific’s other subsidiaries. As a result, the notes will be structurally subordinated to all indebtedness and other liabilities of Boston Scientific’s other subsidiaries (including liabilities to trade creditors) and the guarantees will be structurally subordinated to all indebtedness and other liabilities of all of Boston Scientific’s other subsidiaries, which